Table 1.
Compound | Cluster | Type | SGLT1‐IC50 (μmol/L) | SGLT2‐IC50 (μmol/L) | ||||
---|---|---|---|---|---|---|---|---|
n | Mean | SD | n | Mean | SD | |||
Phloridzin | Glycosides | Natural | 25+ | 0.34 | 0.14 | 29+ | 0.16 | 0.1 |
(+)‐pteryxin | APC | Natural | 5 | 12 | 2 | 4 | 9 | 4 |
(+)‐ε‐viniferin | Viniferin‐like | Natural | 4 | 58 | 18 | 2 | 110, 110 | n.a. |
Quinidine | Quinidine‐like | Natural | 2 | 51, 74 | n.a. | 2 | 72, 40 | n.a. |
Cloperastine | Diphenhydramine‐like | Synthetic | 4 | 9 | 3 | 6 | 9 | 7 |
Bepridil | Trimipramine‐like | Synthetic | 4 | 10 | 5 | 8 | 14 | 12 |
Trihexyphenidyl | Trihexyphenidyl‐like | Synthetic | 3 | 12 | 1 | 7 | 20 | 13 |
Bupivacaine | Bupivacaine‐like | Synthetic | 4 | 23 | 14 | 5 | 43 | 29 |
IC50‐values of the most active novel inhibitors from chemical clusters presented in Figure 2. Results are means with SD from biological replicates, or individual measurements. n.a. = not applicable. + = original dataset contained a statistical outlier that was excluded from calculation of the mean and SD.